Pfizer is currently conducting clinical trials for the drug Tofacitinib CAS# 540737-29-9, as a non injectable treatment for Rheumatiod Arthritis, as well as Psoriasis. Tofacitinib is also being investigated as potential treatment for inflammatory bowel disease, a preventative for organ transplant rejection, and other immunological diseases. Both five and ten milligram doses are slated to be offered, introducing an alternative treatment to current RA drugs, such as Abbott’s injectable drug Humira.
Developed to target the JAK protein, which is the protein that leads to joint destruction in RA patients, Tofacitinib has shown itself to be a viable competitor in trials thus far. Phase 3 trials that began in 2007 are planned to continue through 2015, with a phase 3 trial also underway for the treatment of Psoriasis.
Patients participating in the clinical trials were either dosed at five or ten milligrams, taken twice daily. Initial, as well as long term results have shown the drug to be safe and free of adverse side effects. There were four documented deaths at the beginning of the clinical trials, but Pfizer determined only one death was actually due to Tofacitinib.
On December 20, 2011 Pfizer announced that the U.S. Food and Drug Administration (FDA) had accepted for review the New Drug Application (NDA) for Tofacitinib . Described as a new, investigational oral JAK inhibitor, Tofacitinib is for the treatment of adult patients with moderate to severely active Rheumatoid Arthritis.
This immunosuppressant drug is supplied by LGM Pharma for R&D purposes and is available for prompt shipment.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.